NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results Abstract #1508

Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.
Aim(s): Evaluate the activity and safety of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera®) in patients with advanced, progressive sstr positive midgut NETs.
Materials and methods: 230 patients grade 1-2 metastatic midgut NETs were randomized to Lutathera 7.4 GBq every 8 weeks (x4 administrations) vs Octreotide LAR 60 mg every 4 weeks. Primary endpoint was PFS (RECIST 1.1) with tumor assessment every 12 weeks. Secondary objectives included ORR, OS, toxicity and QoL.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Jonathan Strosberg
Keywords: Lutathera, PRRT, NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
#1437 Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study
Introduction: In the phase 3, RADIANT-4 study, everolimus (EVE) improved median progression-free survival (PFS) by 7.1 months in patients (pts) with advanced, progressive, nonfunctional NET of lung or GI tract compared to placebo (PBO); HR, 0.48; 95%CI, 0.35-0.67; P<0.00001.
Conference: 13th Annual ENETS conference (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. Nicola Fazio
#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis
Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Simron Singh
#1505 A Blood-Based Multi-Transcript Test, the NETest, Predicts and Defines PRRT Efficacy in Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective NET treatment. Predicting response is based on somatostatin receptor expression and efficacy evaluated by RECIST criteria. Both have limited accuracy. The NETest measures tumor activity in blood and correlates cell signaling and metabolism directly with tumor activity.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Professor Mark Kidd
Authors: Bodei L, Kidd M, Severi S, Drozdov I, ...
Keywords: NETest, PRRT